Rabinowitz Matthew sold $642K of NTRA (indirect holdings)
Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 2,000 indirectly-held shares of Natera, Inc. (NTRA) at $320.90 ($0.64M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
Natera, Inc.
Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 2,000 indirectly-held shares of Natera, Inc. (NTRA) at $320.90 ($0.64M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
Sheena Jonathan sold 9,150 shares of Natera, Inc. (NTRA) at an average of $315.66 ($308.40–$320.90, $2.89M total) across 10 trades on 2026-08-07 under a Rule 10b5-1 trading plan.
Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.
Over the past 7 days, alphai's AI scored 13 news stories mentioning NTRA (Natera, Inc.). Coverage has skewed bullish: 11 bullish, 2 neutral, and 0 bearish.
Recent NTRA coverage spans earnings, insider activity and market movers.
In the last 30 days, NTRA insiders filed 62 SEC Form 4 transactions — no purchases and 62 sales ($12.0M). The most active reporter was Sheena Jonathan with 27 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
This is a routine insider sale under a pre-arranged 10b5-1 plan, with limited signal value for near-term fundamentals.
This is a routine insider sale disclosure, not an operational or financial update, but it can slightly affect near-term sentiment and positioning.
Beat plus guidance hike likely drives near-term repricing and momentum trading, with additional upside from PMDA submission for Signatera.
The article attributes the move to an earnings beat plus a guidance hike, implying near-term repricing and momentum continuation risk.
The text frames a post-earnings upside catalyst via a Q2 beat and raised 2026 revenue outlook, driving momentum trading.
alphai scores every news story that mentions NTRA with an AI model for sentiment and relevance, and aggregates insider trades from Natera, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 2,000 indirectly-held shares of Natera, Inc. (NTRA) at $320.90 ($0.64M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
2 min readSheena Jonathan sold 9,150 shares of Natera, Inc. (NTRA) at an average of $315.66 ($308.40–$320.90, $2.89M total) across 10 trades on 2026-08-07 under a Rule 10b5-1 trading plan.
1 min readNatera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.
6 min readNatera Inc. (NASDAQ: NTRA) shares rose about 21% after the company reported Q2 revenue of $752.8M versus $661.2M consensus and a smaller-than-expected Q2 loss of $0.47 per share. Natera also raised 2026 revenue guidance to $2.85B to $2.91B from $2.74B to $2.82B.
6 min readNatera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.
6 min readNatera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.
6 min readNatera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.
4 min readNatera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.
6 min readU.S. July payrolls contracted, with 23,000 jobs lost versus 80,000 forecast, and May-June payrolls revised down by 103,000. Hourly earnings rose 0.1% monthly and 3.2% yearly. Fed rate-hike odds for September fell to 42%. Stocks hit records; Atlassian (+30.8%), Twilio (+30.6%), and Trade Desk (-21%) moved on earnings.
7 min readA Yahoo Finance AlphaSpace market check said stocks rose early as a weak jobs report supported expectations the Federal Reserve will hold rates. The Nasdaq Composite (^IXIC) gained about 0.5%. The article highlights SpaceX (SPCX) remarks on Starlink targeting AT&T, Verizon and T-Mobile, and Musk comments on building 20 gigawatts of power, affecting telecom and power-related stocks, plus Nvidia (NVDA) after SpaceX chose Nvidia.
7 min read